Loading
Estrogen Receptor Antagonist / CDK4 Inhibitor / Aromatase Inhibitor · Phase 1 Trial
ClinicalTrials.gov · August 14, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 1 trial registration evaluating the novel KAT6A/B inhibitor BG-75202 as monotherapy and in combination with CDK4 inhibitors, estrogen receptor antagonists, and aromatase inhibitors in advanced breast cancer and other solid tumors. No results are posted in this registry record; the study is currently recruiting and remains in early-stage safety and preliminary efficacy assessment.
Phase 1, Interventional, Non Randomized, Sequential, Open label, Treatment purpose. Breast Cancer, Advanced Solid Tumor; age from 18 Years. Intervention: Part 1A: Dose Escalation and Safety Expansion, BG-75202 Mon…; Part 1B: Dose Escalation and Safety Expansion, BG-75202 + E…; Part 2A: Dose Optimization, BG-75202 + Estrogen Receptor An…; Part 2B: Safety Run-In, BG-75202 + CDK4 inhibitor + A…. n = 86. 31 sites across 6 countries.
This is a Phase 1 trial registration evaluating the novel KAT6A/B inhibitor BG-75202 as monotherapy and in combination with CDK4 inhibitors, estrogen receptor antagonists, and aromatase inhibitors in advanced breast cancer and other solid tumors. No results are posted in this registry record; the study is currently recruiting and remains in early-stage safety and preliminary efficacy assessment.
This is a registry record; no efficacy or safety results are reported. Phase 1 design is exploratory; primary focus is safety and dose selection rather than clinical benefit.
This early-phase study cannot yet inform clinical practice. Clinicians should monitor for future results regarding the safety profile and preliminary efficacy of BG-75202-based combinations, which may establish a foundation for later-phase development.
Phase 1 trial in early-stage development assessing safety and preliminary antitumor activity; no results reported in this registry record.
As stated by the source record.
Quoted from the source exactly as published.
This early-phase study cannot yet inform clinical practice. Clinicians should monitor for future results regarding the safety profile and preliminary efficacy of BG-75202-based combinations, which may establish a foundation for later-phase development.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07222267). This is a study registration, not published results. Lead sponsor: BeOne Medicines. Recruitment status: RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 86 participants (ESTIMATED). Conditions: Breast Cancer, Advanced Solid Tumor. Interventions: DRUG: BG-75202; DRUG: CDK4 Inhibitor; DRUG: Estrogen Receptor Antagonist; DRUG: Aromatase Inhibitor. Primary outcome measures: Part 1: Number of Participants with Adverse Events (AEs) , From first dose to 30 days after last dose or initiation of a new anticancer therapy, whichever occurs first, up to approximately 12 months; Part 1: Recommended Dose for Expansion (RDFE) , Estimated approximately 1 year; Part 2: Overall Response Rate (ORR) , Up to approximately 2 years. Brief summary: The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75202 (KAT6A/B inhibitor) alone and in combination with other therapies in participants with breast cancer and other advanced solid tumors.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.